⌘K
t
On 15 January 2026, Roquefort Therapeutics plc announced that its broker, SP Angel Corporate Finance LLP, published a new research note. This note concerns the company's proposed transaction with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc., which was first announced on 8 September 2025. The research note can be accessed via the company's website.
15 January 2026
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Research Note Published
Roquefort Therapeutics plc (LSE:ROQ), the Main Market listed biotech company, announces that a new research note regarding the Company's proposed transaction with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc., as first announced on 8 September 2025, has been published by its broker SP Angel Corporate Finance LLP.
It can be accessed by the following link: https://www.roquefortplc.com/analyst-research
ENDS
|
Roquefort Therapeutics plc |
+44 (0)20 3918 8633 |
|
Stephen West (Chairman) / Dr Darrin Disley (Interim MD) |
|
|
SP Angel Corporate Finance LLP (Broker to the Company) David Hignell / Vadim Alexandre / Devik Mehta |
+44 (0)20 3470 0470
|
|
Shard Capital Partners LLP (Broker to the Company) Damon Heath |
+44 (0)20 4530 6926
|
|
Burson Buchanan (Public Relations) Ben Romney / Jamie Hooper |
+44 (0)20 7466 5000
|
LEI: 254900P4SISIWOR9RH34
For further information on Roquefort Therapeutics, please visit www.roquefortplc.com
About Coiled Therapeutics Inc. ("Coiled USA")
Coiled USA is a clinical stage oncology company and is a spin-out of A2A Pharmaceuticals, Inc. Coiled USA holds the exclusive worldwide rights to AO-252, a novel, brain-penetrant small molecule inhibitor designed to disrupt TACC3 protein-protein interactions. Coiled USA has advanced the AO-252 program through pre-clinical development and IND approval and commenced Phase I trials in the USA (trials ID: NCT06136884). Coiled USA is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments.
About A2A Pharmaceuticals, Inc. ("A2A Pharmaceuticals")
A2A Pharmaceuticals is a private, well-funded company that uses proprietary computational systems, including generative AI with its SCULPT™ platform to accelerate the development of novel drug alternatives for life threatening diseases like cancer. This enables a more efficient process than traditional trial and error approaches to drug discovery.
A2A Pharmaceuticals aims to develop therapies to early clinical stages and then spin them out into standalone entities to progress them through clinical development. In 2018, A2A Pharmaceuticals spun out its MLL-Menin program to Biomea Fusion, Inc. ("Biomea Fusion"), a company that completed an IPO on Nasdaq in 2021 raising US$153 million and listing with a market capitalisation of US$464 million. Post-IPO Biomea Fusion's market capitalisation reached a peak of over US$1 billion.
Further information on A2A Pharmaceuticals can be found at: https://www.a2apharma.com/